Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ProMIS Neurosciences Inc. - Common Shares (NQ:PMN)

0.4500 +0.0100 (+2.27%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jul 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ProMIS Neurosciences Inc. - Common Shares

< Previous 1 2 3 4 Next >
ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
From ProMIS Neurosciences Inc.
Via GlobeNewswire
PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q1 2024
PMN stock results show that ProMIS Neurosciences beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
Study results support differentiation of PMN310 from other amyloid-beta-directed antibodies 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic... 
Via Benzinga
Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 300 points on Monday. The Dow traded up 0.89% to 38,321.05 while the NASDAQ rose 0.70% to 16,288.03. The S&P 500 also... 
Via Benzinga
Topics Stocks
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
Study results support ProMIS’ TDP-43 misfolding-specific epitope as a potential therapeutic target for Amyotrophic Lateral Sclerosis (ALS) 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April
From ProMIS Neurosciences Inc.
Via GlobeNewswire
PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q4 2023
PMN stock results show that ProMIS Neurosciences beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
Adds Key U.S. and International Patent Allowances to Further Protect the Company’s Monoclonal Antibody Therapeutic for the Treatment of Alzheimer’s Disease 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
Lead vaccine candidate selected for advancement against synucleinopathies including Multiple System Atrophy, Parkinson’s disease and Dementia with Lewy bodies 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Issues Letter to Shareholders
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode... 
Via Benzinga
ProMIS Neurosciences, Inc. Announces Leadership Transition
Appoints Neil Warma, Industry Leader and ProMIS Board Member, as Interim Chief Executive Officer 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Announces Publication on Novel Target for ALS
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease
Advances novel monoclonal antibody designed to be highly selective for toxic oligomers of amyloid-beta (Aβ) in first-in-human study 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 3, 2023
Via Benzinga
ProMIS Neurosciences Closes $20.4 Million Private Placement Financing
At-the-Market fundraise to support Company through several potentially value-creating milestones and beyond 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Crude Oil Falls; Dick's Sporting Goods Earnings Miss Views
U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones falling over 100 points on Tuesday. The Dow traded down 0.39% to 34,330.87 while the NASDAQ rose 0.24% to 13,530.50. The... 
Via Benzinga
Topics Earnings Stocks
Why Macy's Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) shares jumped 42.8% to $5.60 after the FDA lifted clinical hold on the company’s FTX-6058 for sickle cell disease. 
Via Benzinga
Why ProMIS Neurosciences Shares Are Trading Higher By 33%; Here Are 20 Stocks Moving Premarket
Gainers Axcella Health Inc. (NASDAQ: AXLA) shares gained 65% to $0.2887 in pre-market trading after gaining 12% on Monday. The company recently posted a narrower-than-expected quarterly loss. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off Tuesday with a breakdown of the biggest pre-market stock movers investors will want to keep an eye on! 
Via InvestorPlace
ProMIS Neurosciences Announces $20.4 Million Private Placement Financing
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Why Biophytis Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket
Gainers Biophytis S.A. (NASDAQ: BPTS) shares surged 53.9% to $3.31 in pre-market trading after the company signed a partnership with SEQENS to produce Sarconeos (BIO101) active compound, the company's... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.